

Treatment of Inflammatory Diseases

Reference Number: RDF1805-23

Date of Response: 18/09/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Freedom of Information Officer,

I am conducting analysis on drugs used to treat inflammatory diseases. I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of May 2023 to the end of July 2023 (or the latest available 3 months).

- 1. How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023? Please ignore any cells which have been blanked out.*

Answer: Please see table below representing the latest 3 months available May to July 2023.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis*	Rheumatoid arthritis
Adalimumab (Humira)	10	≤5	≤5	6	≤5	6
Adalimumab (Biosimilars)	165	337	41	89	28	138
Apremilast	7			8		
Bimekizumab	≤5					
Brodalumab	9					
Certolizumab Pegol	9			13	4	40
Deucravacitinib	0					
Etanercept (Enbrel)	0			0	≤5	≤5
Etanercept (Biosimilars)	≤5			14	9	79
Guselkumab	26			≤5		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	0	162	87	≤5	≤5	13
Ixekizumab	34			15	≤5	
Risankizumab	35	0		≤5		
Secukinumab	51			29	9	
Tildrakizumab	22					
Ustekinumab	54	151	20	≤5		

Upadacitinib		12	65	6	≤5	49
Vedolizumab		50	130			
Filgotinib			19			36
Golimumab			≤5	30	29	26
Mirikizumab			0			
Ozanimod			0			
Tofacitinib			58	6	0	14
Abatacept						26
Baricitinib						91
Rituximab						19
Sarilumab						11
Tocilizumab						33

*(inc. axial spondylitis)

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

2. *How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023? Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.*

Answer: Please see table below representing the latest 3 months available May to July 2023.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	16	6	24
Adalimumab (Biosimilars)	201	394	326
Apremilast	7	0	9
Bimekizumab	≤5	0	0
Brodalumab	9	0	0
Certolizumab Pegol	10	0	68
Deucravacitinib	0	0	0
Etanercept (Enbrel)	0	0	≤5
Etanercept (Biosimilars)	≤5	0	119
Guselkumab	26	0	≤5
Infliximab (Remicade)	0	0	≤5
Infliximab (Biosimilars)	0	183	27
Ixekizumab	34	0	16
Risankizumab	35	≤5	≤5
Secukinumab	55	0	46
Tildrakizumab	22	0	0

<i>Ustekinumab</i>	55	174	≤5
<i>Upadacitinib</i>	8	79	106
<i>Vedolizumab</i>	0	158	0
<i>Filgotinib</i>	0	20	44
<i>Golimumab</i>	0	≤5	96
<i>Mirikizumab</i>	0	0	0
<i>Ozanimod</i>	0	≤5	0
<i>Tofacitinib</i>	≤5	59	20
<i>Abatacept</i>	0	0	29
<i>Baricitinib</i>	≤5	0	92
<i>Rituximab</i>	0	0	41
<i>Sarilumab</i>	0	0	12
<i>Tocilizumab</i>	0	0	58